Alivus Life Sciences

Price chart

Previous close

₹1,558.70

Open

₹1,526.40

Day high

₹1,554.00

Day low

₹1,490.10

Listed on NSE since 6 August 2021.

Market value

₹18,207 Cr

P/E (trailing)

27.20

EPS (trailing)

₹54.43

Price to book

5.01

Dividend yield

0.34%

Return on equity

20.2%

Debt to equity

0.01

Profit margin

24.9%

Beta

0.05

Volume today

4.51 L

Average volume

2.03 L

Source: Yahoo Finance. Ratios use the latest reported (trailing twelve-month) figures.

Source: Yahoo Finance, from annual reports. Consolidated where reported.

Source: Alivus Life Sciences’s results filed with NSE, standalone (the company alone). Net profit is the share of Alivus Life Sciences’s own shareholders where the filing separates it. Profit vs year ago compares with the same quarter a year earlier; – where that quarter is not on file or made a loss.

Download results (zip) A spreadsheet of the quarterly results and balance sheets, with the original filings from NSE.

Source: Alivus Life Sciences’s half-yearly statements of assets and liabilities filed with NSE, standalone. Companies file these every September and March.

Alivus Life Sciences Limited develops and manufactures active pharmaceutical ingredients in India, the United States, Europe, Japan, Russia, Brazil, South Korea, Taiwan, Canada, China, and Australia. It offers various APIs, such as amiodarone, ezetimibe, lithium carbonate, oxcarbazepine, mirabegron, solifenacin, atovaquone, etoricoxib, dapagliflozin, and sitagliptin for therapeutic areas, including cardiovascular, central nervous system, diabetes, oncology, urology, and pain management, as well as anti-fungal, anti-histaminic, anti-acne, anti-emetics immunomodulators, anti-ulceratives, immunosuppressant, respiratory agent, ophthalmologic agent, anti-spasmodic, and urology. The company also provides contract development and manufacturing comprising process development, analytical development and support, and API and intermediate manufacturing; and research and development, intellectual property, quality and compliance, customer experience, regulatory support. In addition, it exports its products. The company was formerly known as Glenmark Life Sciences Limited and changed its name to Alivus Life Sciences Limited in December 2024. The company was founded in 2001 and is based in Mumbai, India. Alivus Life Sciences Limited operates as a subsidiary of Nirma Limited.

Industry

Drug Manufacturers - Specialty & Generic

Based in

Mumbai

Employees

2,272

Company website · Profile: Yahoo Finance

No headlines name Alivus Life Sciences in the last day or two.

• Dividend - Rs 5 Per Share

  Dividend · ex-date 1 September 2026

• Dividend - Rs 5 Per Share

  Dividend · ex-date 1 September 2025

• Interim Dividend - Rs 22.50 Per Share

  Dividend · ex-date 17 October 2023

• Annual General Meeting

  Action · ex-date 22 September 2023

• Interim Dividend - Rs 21 Per Share

  Dividend · ex-date 24 March 2023

• Dividend - Rs 10.5 Per Share

  Dividend · ex-date 15 September 2022

• Interim Dividend - Rs 10.50 Per Share

  Dividend · ex-date 22 November 2021 · record date 23 November 2021

Source: NSE. Latest first.